Aguettant, an independent French pharmaceutical company, and PX´Therapeutics, a French Contract Manufacturing Organization dedicatedto the development of recombinant proteins, join forces to boost theiractivities

Aguettant, a pioneer in drugs for injection since 1903, invests in the field of biotechnologies. Aguettant Biotech, a fully-owned subsidiary of Aguettant Santé, acquires a majority stake in the equity of PX´Therapeutics.

PX´Therapeutics, a specialist in protein engineering and development of protein and antibody therapeutics from the early research stage through to the preclinical and clinical phase I/II production, will benefit greatly from joining Aguettant group. The company will expand and further strengthen its services to customers by increasing its manufacturing capabilities to industrial scale, to support late-stage clinical studies and commercial scale production.

Through this operation, Aguettant creates a capability to develop biotechnology products in the future, alone or in partnership with other companies.

PX´Therapeutics will remain autonomous in its business and fully dedicated to customers´ projects. PX´Therapeutics co-founders, Tristan Rousselle and Nicolas Mouz, will stay as minority shareholders. The company´s management remains under the direction of Tristan Rousselle.

Aguettant

• Family-owned pharmaceutical company based in Lyon, France
• Sales over € 85 M over the past 12 months, of which more than 20% abroad
• 3 development axis:
  • designing and industrialising innovative drug delivery systems for enhanced security in emergency medicine,
  • offering a range of essential micro-nutrients capable of preventing and curing critical deficiencies,
  • taking care of patients suffering from severe symptoms of Parkinson´s disease.
• Main project in progress: building a new R&D and manufacturing unit with the prospect of boosting innovation capabilities and enhancing international growth.

PX´Therapeutics

• Based in Grenoble and in Lyon, France
• Established in 2000
• Over 50 employees
• Turnover : € 4 M + € 4.5 M of other revenues (2011)
• 190 clients "´ 60% of the turnover is generated from customers outside France
• Over 800 recombinant protein and monoclonal antibodies projects performed so far "´ several clinical batches produced are currently in phase I and II clinical trials in Europe and the USA.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50427548〈=en